Cobimetinib + Atezolizumab + Pembrolizumab
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced BRAFV600 Wild-type Melanoma
Conditions
Advanced BRAFV600 Wild-type Melanoma
Trial Timeline
Dec 11, 2017 → Feb 19, 2021
NCT ID
NCT03273153About Cobimetinib + Atezolizumab + Pembrolizumab
Cobimetinib + Atezolizumab + Pembrolizumab is a phase 3 stage product being developed by Roche for Advanced BRAFV600 Wild-type Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03273153. Target conditions include Advanced BRAFV600 Wild-type Melanoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced BRAFV600 Wild-type Melanoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03273153 | Phase 3 | Terminated |
Competing Products
20 competing products in Advanced BRAFV600 Wild-type Melanoma